ReviewDrugs & aging2014
Managing moderate-to-severe psoriasis in the elderly.
Review in Drugs & aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 72 citations in OpenAlex.
- Clinical efficacy analysis of secukinumab combined with calcipotriol cream in the treatment of moderate to severe psoriasis in elderly patients.BMC pharmacology & toxicology · 2026Article
- Narrowband ultraviolet B phototherapy for dermatoses seen in elderly: a real-life experience.Lasers in medical science · 2026Observational
- Systemic Biologic Treatment for Psoriasis in Elderly Patients.Journal of clinical medicine · 2025Article
- Geriatric Psoriasis: Evaluation of Clinical Features, Disease Course, and Treatment Modalities of Patients from a Tertiary Care Hospital.Dermatology practical & conceptual · 2025Article
- Safety profile of vunakizumab in elderly patients with moderate-to-severe plaque psoriasis: aFrontiers in medicine · 2025Article
- Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study.Journal of clinical medicine · 2023Article
- Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus.Dermatology reports · 2023Article
- Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.Clinical, cosmetic and investigational dermatology · 2023Article
- Therapy of PsO in Special Subsets of Patients.Biomedicines · 2022Review
- Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study.Acta dermato-venereologica · 2022Article
- Medicinal Treatment of Elderly Psoriasis Patients before and after Entering a Nursing Home.Healthcare (Basel, Switzerland) · 2022Article
- Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.Drugs & aging · 2022Observational
- Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World.Life (Basel, Switzerland) · 2021Article
- Review
- Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis.Acta dermato-venereologica · 2020Article
- Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.Drugs & aging · 2020Article
- Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups.Acta dermato-venereologica · 2020Article
- Management of inflammatory rheumatic conditions in the elderly.Rheumatology (Oxford, England) · 2019Review
- A Case of Nail Psoriasis Successfully Treated with Intralesional Methotrexate.Dermatology and therapy · 2018Article
- [Insufficient tetanus vaccination protection in psoriasis and systemic immunosuppression : Results of a retrospective investigation of 101 patients].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Managing psoriasis in the elderly can be difficult for physicians, who must consider comorbidities, the resulting polypharmacy, and progressive functional impairment of several organs. Indeed, topical agents are the first-line treatment for limited disease. Phototherapy is recommended if topical drugs are not sufficient and the patient has multiple comorbidities and risk factors that make them a poor candidate for an oral or injectable systemic agent. The most important pharmacokinetic alteration in the elderly population is the decreased excretory capacity of the kidney; thus, cyclosporine should be considered a last resort treatment, and the administered dose of methotrexate should be lowered according to the reduction in estimated creatinine clearance. Acitretin can be used in the absence of severe renal insufficiency, paying attention to lipid profile, treating eventual hyperlipidemia, and closely monitoring liver enzymes. Available data on biological drugs in the elderly are limited. Biologics are associated with a small but significant overall risk of infections. However, there is no convincing evidence that the relative risk of infection with anti-tumor necrosis factor (TNF)-α therapy increases with age. Nevertheless, the package inserts for biologics recommend caution when administering these medications to the geriatric population, due to the high baseline risk of infection in such patients. Etanercept seems to be well tolerated, possibly because of its lower immunosuppressive characteristics compared with other biologics. However, studies with larger sample sizes are needed to confirm its safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.